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Running title:  
Lenalidomide-based regimens in elderly MM 
 
Abstract 
In the EMN01 trial, the addition of an alkylator (melphalan or cyclophosphamide) to 
lenalidomide-steroid induction has been prospectively evaluated in transplant-ineligible 
multiple myeloma patients. After induction, patients were randomly assigned to maintenance 
treatment with lenalidomide alone or with prednisone continuously. This analysis (median 
follow-up of 71 months) focused on maintenance treatment and on subgroup analyses 
according to the International Myeloma Working Group Frailty Score. 217 patients in 
lenalidomide-dexamethasone, 217 in melphalan-prednisone-lenalidomide and 220 in 
cyclophosphamide-prednisone-lenalidomide arms were evaluable. 284 (43%) patients were 
fit, 205 (31%) intermediate-fit and 165 (25%) frail. After induction, 402 patients were eligible 
for maintenance, (lenalidomide arm: 204; lenalidomide-prednisone: 198). After a median 
duration of maintenance of 22.0 months, progression-free survival from start of maintenance 
was 22.2 months with lenalidomide-prednisone vs 18.6 months with lenalidomide (HR 
0.85,p=0.14), with no differences across frailty subgroups. The most frequent grade ≥3 
toxicity was neutropenia (10% of lenalidomide-prednisone and 21% of lenalidomide patients; 
p=0.001). Grade ≥3 non-hematologic adverse events were rare (<15%). In fit patients, 
melphalan-prednisone-lenalidomide significantly prolonged progression-free survival 
compared to cyclophosphamide-prednisone-lenalidomide (HR 0.72,p=0.05) and 
lenalidomide-dexamethasone (HR 0.72, p=0.04). Likewise, a trend towards a better overall 
survival was noted for melphalan-prednisone-lenalidomide and cyclophosphamide-
prednisone-lenalidomide, as compared to lenalidomide-dexamethasone. No differences were 
observed in intermediate-fit and frail patients. This analysis showed positive outcomes of 
maintenance with lenalidomide-based regimens, with a good safety profile. For the first time, 
we showed that fit patients benefit from a triplet full-dose regimen, while intermediate-fit and 
frail patients from gentler regimens.  
ClinicalTrials.gov registration number: NCT01093196. 
 
Keywords: newly diagnosed multiple myeloma, elderly patients, lenalidomide, maintenance, 
prednisone, induction, melphalan, cyclophosphamide, fit, intermediate-fit, frail. 
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Introduction 
In the last decade, the increased use of novel agents as initial therapy for multiple myeloma 
(MM) significantly improved overall survival (OS) in patients ineligible for autologous 
transplantation.
1
 In Europe, two triplet regimens – bortezomib-melphalan-prednisone (VMP) 
and melphalan-prednisone-thalidomide (MPT) – are considered standards of care for elderly 
patients ineligible for autologous stem-cell transplantation (ASCT).
2,3
 Recently, based on the 
results of the MM020 trial, a new doublet regimen with no alkylating agent has been 
introduced as a new standard for the treatment of transplant-ineligible patients with newly 
diagnosed MM (NDMM). Indeed, that study prospectively compared outcomes of MPT vs 
lenalidomide and low-dose dexamethasone (Rd), and found that Rd until disease progression 
(PD) improved progression-free (PFS) and overall survival (OS), as compared with MPT.
4
 The 
phase 3 trial MM-015 showed that melphalan-prednisone-lenalidomide (MPR) followed  by  
maintenance  with  lenalidomide significantly prolonged PFS, as compared with MP or MPR 
without maintenance.
5
  
Maintenance therapy with lenalidomide improves outcome and its role has been extensively 
investigated both in ASCT-eligible and -ineligible patients. A recent meta-analysis of three 
randomized phase 3 trials confirmed PFS and OS advantages for lenalidomide maintenance 
after ASCT vs. placebo or observation. In the MM-015 trial, elderly patients were treated with 
lenalidomide as induction and maintenance, which reduced the risk of progression by 51% 
compared to lenalidomide as induction without maintenance.
5
 In the Myeloma XI trial, 
lenalidomide maintenance reduced the risk of progression by 56% in comparison with 
observation.
6
 Moreover, in this trial both ASCT-eligible and -ineligible patients benefited from 
lenalidomide maintenance. 
The advantage of adding steroids to immunomodulatory drugs (IMiDs) during maintenance is 
unclear. In young patients eligible for ASCT, after a median follow-up of 41 months, median 
PFS and OS did not differ significantly between lenalidomide plus prednisone and 
lenalidomide alone. No data are available in elderly patients ineligible for ASCT.
7
 
 
The choice of best treatment for each patient is troublesome, especially in elderly patients, 
since they represent a heterogeneous population in terms of both physical and psycho-social 
functioning. Furthermore, it is now accepted that chronological and biological ages may not 
correspond, and that the presence of frailty, comorbidities and disabilities can affect therapy 
endurance. The OS of frail patients is impaired due to toxic side effects from first-line 
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treatment that may preclude second-line treatment, with third-line therapies in >80-year old 
MM patients being extremely rare. The “one size fits all” is no longer a suitable approach, and 
many recommendations suggested that fit patients may benefit from triplet regimens, while 
intermediate-fit and frail patients may benefit from doublet regimens.
8,9
 There are no data 
from prospective trials supporting these recommendations and a formal comparison between 
an alkylator-containing triplet regimen vs. an alkylator-free doublet regimen, both including 
lenalidomide, has not yet been performed. 
The EMN01 study was designed to compare the PFS of triplet vs doublet induction regimens 
and the PFS of lenalidomide-prednisone vs lenalidomide alone as maintenance treatments. 
Furthermore, before treatment, a geriatric assessment to assess patients’ frailty status 
according to the International Myeloma Working Group (IMWG) Frailty Score had been 
performed. With this analysis, after more than 5 years of follow-up, we would like to report 
the safety and efficacy of maintenance treatment in our patients and to perform a post-hoc 
analysis according to frailty status in both induction and maintenance treatment arms. 
 
 
Methods 
 
Study Design 
The study was conducted in 58 Italian and 9 Czech centers between August 2009 and 
September 2012. The details of this multicenter randomized (1:1:1) phase 3 trial had already 
been reported and have been updated here after a median follow-up of 71 months for 
survivors.
10
 Briefly, 662 NDMM patients ineligible for high-dose therapy plus ASCT because of 
age (≥65 years) or coexisting comorbidities have been enrolled. The study was approved by 
the institutional review boards at each of the participating centers and registered at 
ClinicalTrials.gov (NCT01093196). All patients gave written informed consent before entering 
the study, which was performed in accordance with the Declaration of Helsinki. 
Per protocol, patients were stratified by age (≤75 vs >75 years). Based on the recent IMWG 
geriatric score that stratifies patients according to their frailty status (fit, intermediate-fit, and 
frail),
11
 a post-hoc analysis including age (≤75 vs 76-80 vs >80 years), comorbidities 
(according to the Charlson score) and cognitive/physical status (according to the Activities of 
Daily Living and the Instrumental Activities of Daily Living scores) was conducted (Table S1). 
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Procedures 
Six hundred fifty-four patients were randomly assigned to receive induction (Figure S1) with 
nine 28-day cycles of Rd (n=217) or MPR (n=217) or cyclophosphamide-prednisone-
lenalidomide (CPR) (n=220). Rd patients received lenalidomide 25 mg/day for 21 days; 
dexamethasone 40 mg on days 1,8,15,22 in patients 65-75 years old and 20 mg in those >75 
years of age. MPR patients received lenalidomide 10 mg/day for 21 days; oral melphalan 0.18 
mg/Kg for 4 days in patients 65-75 years old and 0.13 mg/Kg in those >75 years of age; 
prednisone 1.5 mg/Kg for 4 days. CPR patients received lenalidomide 10 mg/day for 21 days; 
oral cyclophosphamide 50 mg every other day (eod) for 28 days in patients 65-75 years old 
and 50 mg eod for 21 days in those >75 years of age; prednisone 25 mg eod. After induction, 
patients were randomized to receive maintenance treatment with lenalidomide alone (R) 10 
mg on days 1-21 every 28 days, or in combination with prednisone (RP) 25 mg eod 
continuously. After the inclusion of the first 120 patients, the protocol was amended to 
increment the doses of lenalidomide and cyclophosphamide in patients 65-75 years old in the 
CPR group, due to negligible toxicities in comparison with the two other treatment arms. 
Therefore, CPR induction schedule was changed to lenalidomide 25 mg/day for 21 days and 
oral cyclophosphamide 50 mg/day for 21 days.  
 
Statistical Analysis 
Updated analyses were performed by using data collected on October 31, 2017. All the results 
were evaluated on an intention-to-treat basis. For univariate analyses, the time-to-event 
curves were estimated by the Kaplan-Meier method and compared using the log-rank test. 
Time to event was expressed as median with interquartile range or 5-year Kaplan-Meier 
estimate. The Cox proportional hazards model was used to estimate the HR values and the 
95% confidence intervals (CIs).  
Data were analyzed as of May 2018 by using R (v3.1.1).  
 
 
Results 
A total of 654 patients were randomly assigned to receive induction with Rd (n=217) or MPR 
(n=217) or CPR (n=220; Figure S1). Baseline demographics and disease characteristics were 
previously reported
10
 and were well balanced among the three groups. Median age was 73 
years in the Rd and CPR arms, 74 years in the MPR arm. Twenty-five percent of patients were 
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classified as frail and were well distributed among the treatment arms. A total of 402 patients 
completed the assigned induction treatment and were randomly allocated to receive 
maintenance with RP (n=198) or R (n=204) (Figure S1, Table 1 for baseline characteristics).  
 
The median follow-up for survivor patients was 71 months from enrollment. Progression or 
death occurred in 177 patients (82%) in the Rd, 166 (76%) in the MPR, and 194 (88%) in the 
CPR groups. The median PFS was 18.6 months with the doublet and 20.8 months with the 
triplet combinations (HR 1.05, 95% CI 0.87-1.25, p=0.62; Figure S2). The median OS was 61.5 
months with doublet and 65.7 months with triplet regimens (HR 1.09, 95% CI 0.87-1.37, 
p=0.47). By comparing the three arms separately, the median PFS was 18.6 months in the Rd, 
22.2 months in the MPR and 18.9 months in the CPR groups (MPR vs CPR: HR 0.78, 95% CI 
0.63-0.96, p=0.02; MPR vs Rd: HR 0.84, 95% CI 0.68-1.04, p=0.11; Figure 1A). The median 
time to next treatment (TNT) was 23.8 months in the Rd, 28.7 months in the MPR and 23.8 
months in the CPR groups (MPR vs CPR: HR 0.79, 95% CI 0.64-0.98, p=0.03; MPR vs Rd: HR 
0.82, 95% CI 0.66-1.02, p=0.07; Figure 1B). The median progression-free survival 2 (PFS-2) 
was 41.2 months in the Rd, 40.2 months in the MPR and 40.8 months in the CPR groups (MPR 
vs CPR: HR 0.90, 95% CI 0.72-1.14, p=0.40; MPR vs Rd: HR 0.94, 95% CI 0.74-1.19, p=0.63; 
Figure 1C). Death occurred in 115 patients (53%) in the Rd, 108 (50%) in the MPR and 107 
(49%) in the CPR groups. The median OS was 61.5 months with Rd, 65.2 months with MPR 
and 66.4 months with CPR (MPR vs CPR: HR 1.03, 95% CI 0.79-1.35, p=0.83; MPR vs Rd: HR 
0.93, 95% CI 0.72-1.22, p=0.61; Figure 1D). The subgroup analysis of induction treatment in 
standard- and high-risk cytogenetic patients showed the same trends observed in the overall 
population (Figure S3). 
A post-hoc analysis according to patient frailty was performed (Figure 2). In fit patients, an 
advantage with the triplet regimen MPR was detected: the median PFS was 21.2 months in Rd, 
25.6 months in MPR and 21.7 months in CPR patients (MPR vs CPR: HR 0.72, 95% CI 0.52-
1.00, p=0.05; MPR vs Rd: HR 0.72, 95% CI 0.52-0.99, p=0.04; Figure 2A). The median OS was
 
50.2 months in the Rd group, shorter than in both MPR (79.9 months) and CPR groups (82.9 
months) (MPR vs CPR: HR 1.11, 95% CI 0.72-1.71, p=0.65; MPR vs Rd: HR 0.75, 95% CI 0.50-
1.12, p=0.16; Figure 2B). In intermediate-fit patients, no advantage of one regimen over the 
others was found: the median PFS was 16.6 months in Rd, 20 months in MPR and 20.9 months 
in CPR patients (Figure 2C). The median OS was not reached in Rd, 60.8 months in MPR and 
66.7 months in CPR arms (Figure 2D). Not even in frail patients, the superiority of one 
7 
 
regimen over the others was found: the median PFS was 18.2 months in Rd, 21.5 months in 
MPR and 13.8 months in CPR patients (Figure 2E). The median OS was 48.2 months with Rd, 
44.7 months with MPR and 40.5 months with CPR (Figure 2F).  
During maintenance, 31% of patients in the RP group and 20% of patients in the R group 
improved their quality of response. In the RP group, the partial response (PR) rate increased 
from 87% to 95%, the very good PR (VGPR) rate from 33% to 58%, and the complete 
response (CR) rate from 5% to 9%. In the R group, the PR rate increased from 83% to 88%, 
the VGPR rate from 33% to 47%, and the CR rate from 2% to 7%. 
After a median follow-up of 62 months from the start of maintenance, progression or death 
occurred in 153 patients (77%) in the RP group and in 164 (80%) in the R group. The median 
PFS was 22.2 months with RP and 18.6 months with R (HR 0.85, 95% CI 0.68-1.06, p=0.14; 
Figure 3A). The median TNT was 32.4 months with RP and 29.8 months with R (HR 0.95, 95% 
CI 0.75-1.20, p=0.67; Figure 3B). In both groups, maintenance therapy delayed the median 
time to next therapy (clinical progression) by approximately 10 months in comparison with 
the median PFS (biochemical progression). The median PFS-2 was 53.3 months with RP and 
42.3 months with R (HR 1.04, 95% CI 0.80-1.35, p=0.79; Figure 3C). Death occurred in 92 
patients (46%) in the RP group and 78 (38%) in the R group. The median OS was 72.3 months 
with RP and not reached with R therapy (HR 1.21, 95% CI 0.89-1.64, p=0.22; Figure 3D). 
Subgroup analysis of maintenance treatment in standard- and high-risk cytogenetic patients 
showed the same trends observed in the overall population (Figure S4). 
A post-hoc analysis according to patient frailty was also performed for the maintenance phase 
(Figure 4) and no significant advantage of one regimen over the other was found. In fit 
patients, the median PFS from start of maintenance was 24.4 months with RP and 19.6 
months with R (HR 0.84, 95% CI 0.60-1.16, p=0.29; Figure 4A). Not even in intermediate-fit 
and frail patients, the superiority of one regimen over the other was found (Figures 4C and 
4E). No difference in OS was detected (Figures 4B, 4D, 4F).  
 
Safety profiles of induction were reported in the initial analysis.
10
 Briefly, the most frequent 
grade ≥3 toxicities were hematologic. At least 1 grade ≥3 hematologic AE was reported in 
29% of Rd, 68% of MPR and 32% of CPR patients (p<0.001). The rate of at least 1 grade ≥3 
non-hematologic AE did not exceed 31% in all the three arms. The most frequent grade ≥3 
non-hematologic toxicities were infections (9% with Rd, 11% with MPR and 6.5% with CPR), 
constitutional adverse events (AEs) (5% with Rd, 9.5% with MPR and 3.5% with CPR) and 
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cardiac toxicities (6% with Rd, 4.5% with MPR and 6% with CPR); no significant differences 
were detected among the three arms. The rate of discontinuation due to AEs was similar in 
the three arms: 14% in the Rd, 18% in the MPR and 15% in the CPR groups. Lenalidomide was 
reduced in 16% of Rd, 21% of MPR and 18% of CPR patients, without significant differences 
among the three arms. 
The incidence of at least 1 hematologic AE was similar in fit, intermediate-fit and frail 
patients. The rate of non-hematologic AEs as well as the rate of discontinuation due to AEs 
increased with the worsening of fitness status (Table S2). Data in each induction treatment 
group are presented in Table 3. Frail patients receiving the alkylating-containing regimens 
had the highest rate of discontinuation due to AEs. 
During maintenance, the most frequent grade ≥3 toxicity was neutropenia, which occurred in 
10% of RP and 21% of R patients (p=0.001; Table 2). Grade ≥3 non-hematologic AEs were 
rare and occurred in <15% of patients. The proportion of patients requiring dose 
discontinuation due to AEs during maintenance was 18% in the R arm and 21% in the RP arm. 
The proportion of patients requiring dose reduction during maintenance was 9% in the RP 
arm and 16% in the R arm (p=0.05). Fifteen cases of second primary malignancies (SPMs) 
were recorded: 6 (3%) in the RP group and 9 (4%) in the R group. All SPMs were solid 
tumors.  
In the RP group, 133 patients required a second line of therapy: 94 (71%) received 
bortezomib, 3 (2%) thalidomide or lenalidomide, 17 (13%) other chemotherapy, 16 (12%) 
died before starting treatment and 3 (2%) were lost to follow-up. In the R group, 138 patients 
required a second line of therapy: 102 (74%) received bortezomib, 3 (2%) thalidomide or 
lenalidomide, 21 (15%) other chemotherapy, 7 (5%) died before starting treatment and 5 
(4%) were lost to follow-up. 
The incidences of at least one hematologic and non-hematologic grade ≥3 AEs were similar in 
fit, intermediate-fit and frail patients. Frail patients had the highest rate of discontinuation 
due to AEs; a trend towards a higher discontinuation due to AEs was found in frail vs fit 
patients (Table S2). Data in each maintenance treatment group are presented in Table 4.  
 
 
Discussion 
One of the aims of this analysis was to compare RP vs R alone as maintenance treatment after 
induction.  
9 
 
While in young ASCT-eligible NDMM patients the use of maintenance therapy is a standard 
approach, its use in elderly MM patients after induction treatment is more debated. 
In our trial, both maintenance regimens improved the quality of response and produced a 
time from biochemical to clinical relapse of approximately 10 months. Indeed, as recently 
described, even when neoplastic plasma cells become lenalidomide-refractory, the 
immunomodulatory effect of lenalidomide on immune cells may help prolong disease 
control.
12
 A trend toward a slight improvement of PFS in the RP arm was noted as compared 
to R alone, while OS data were still immature after only 170 deaths (42% of patients).  
Regarding safety, maintenance treatment with both regimens was feasible with grade ≥3 non-
hematologic AE rates of less than 15%. The only difference between treatment arms was the 
most frequent grade ≥3 neutropenia in the R arm compared to RP that did not translate into a 
higher infection rate. One of the possible explanations of this result is based on the effect of 
prednisone on neutrophils.
13
 Glucocorticoid therapy inhibits L-selectin expression on 
neutrophils that are more prone to enter the bloodstream, delay the migration of circulating 
neutrophils into tissues, produce a direct antiapoptotic effect on these cells and prompt the 
release of young neutrophils from the bone marrow leading to an increased peripheral blood 
neutrophil count. 
While dose discontinuation was not different in the RP and R arms, patients treated with R 
alone more often required dose reductions that slightly impaired the efficacy of maintenance 
treatment. 
The treatment goal in elderly MM patients is not a trivial issue and international guidelines 
suggesting personalized treatment according to patient’s frailty status are currently based on 
expert opinions, without the availability of high-quality evidence.
8,9
 With all the limitations of 
a post-hoc analysis, this is the first analysis to show that fit patients benefit from a full-dose 
triplet regimen while intermediate-fit and frail patients benefit from gentler regimens. 
Indeed, fit patients treated with MPR induction showed a statistically significant PFS 
advantage over CPR and Rd. Intermediate-fit and frail patients did not show any PFS benefit of 
one regimen over the others. 
A higher hematologic AE rate was noted with MPR induction compared to the other treatment 
arms. 
After the amendment, cyclophosphamide dose has been augmented because of the negligible 
AEs, even if, despite the amendment, it could still be underdosed as compared to other 
cyclophosphamide-containing regimens used in younger patients.
14,15
 This issue could have 
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mitigated the PFS impact of cyclophosphamide addition to lenalidomide-steroid doublets 
even in fit patients. 
Hematologic AEs were not dependent on patients’ frailty status, while the rate of non-
hematologic AEs was correlated to the fitness status but not to the type of induction regimen. 
Indeed, physicians’ limitations to effectively treat frail patients are based on their reduced 
organ function reserve leading to a higher rate of non-hematologic toxicity, rather than on the 
hematologic toxicity that is mainly dependent on the treatment itself, as observed with the 
melphalan-containing regimen in this study. 
As expected, frail patients experienced the highest discontinuation rate due to toxicity, and 
discontinuation was more frequent in the alkylator-containing regimens than in the Rd 
doublet. Therefore, it is reasonable to support the choice of a full dose alkylator-containing 
triplet in fit patients, in order to prioritize the efficacy. Conversely, intermediate-fit and frail 
patients could benefit from a gentler regimen, since a better safety profile should be pursued 
in the absence of an advantage in PFS or OS. 
In the FIRST trial, a retrospective proxy algorithm (which calculated data from questionnaires 
on medical history and quality of life) had been used to estimate the IMWG Frailty Score.
16
 In 
that post-hoc analysis, continuous Rd was compared to an alkylator-containing triplet 
regimen; however, differently from our analysis, the novel agent used in the control arm was 
the first-generation IMiD thalidomide. Indeed, in that analysis continuous Rd produced longer 
PFS and OS compared to MPT across all frailty subgroups, with the greatest benefits observed 
in fit patients. No lenalidomide-containing triplets were included in that trial. 
Despite the limitations of inter-trial comparisons, Rd induction produced a shorter PFS in our 
study than in the FIRST study (26 months with continuous Rd and 21 months with Rd given 
for 18 months).
17
 Of note, in that trial Rd was given for a fixed duration of 18 months or 
continuously, while in our trial Rd was given only for 9 months as induction treatment and 
then both maintenance regimens included lenalidomide given at a lower dose (10 mg instead 
of 25 mg) and lower steroid doses or no steroids at all, depending on the treatment arm. The 
same observation, with the same limitations of inter-trial comparisons, can also be applied to 
the control arm of the more recent MAIA study, in which a median PFS of 31.9 months was 
obtained with continuous Rd (even longer than the PFS obtained in the FIRST study with an 
identical regimen).
18
 
However, the role of continuous full-dose treatment vs full-dose induction followed by low-
dose maintenance in frailty-defined elderly patient populations remains an open issue.  
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Recently, initial results from a randomized phase III trial comparing continuous Rd vs Rd 
induction followed by lenalidomide maintenance (Rd-R) in intermediate-fit patients were 
reported.
19
 Notably, in this patient population, continuous Rd did not produce an advantage in 
PFS compared to Rd-R (15.5 months vs 18.3 months). On the other hand, event-free survival 
(progression or death for any cause/lenalidomide discontinuation/hematologic grade 4 or 
non-hematologic grade 3-4 AEs) was significantly better in Rd-R vs continuous Rd.  
These results suggest that at least in intermediate-fit elderly NDMM patients, treatment 
intensity during the maintenance phase can be de-escalated with no negative impact on 
outcome. 
The EMN01 trial had enrolled patients from 2009 to 2012; thereafter, less toxic and more 
effective combinations have begun to be available. For instance, the addition of bortezomib to 
Rd (VRd) led to a clinically meaningful improvement in PFS and OS in NDMM without an 
intent for immediate ASCT, irrespective of patient age.
20
 In NDMM patients, the addition of the 
anti-CD38 mAb daratumumab to VMP or Rd doubled PFS, with mild and manageable 
toxicity.
18,21
 Besides, studies exploring the addition of a mAb to the VRd combination are 
ongoing with very promising early results.
22
 
Contextualizing our data, quadruplets or triplets containing mAbs, IMiDs and/or PIs may be 
the best choices for fit elderly patients. However, there is still the need for safety and efficacy 
data on selected intermediate-fit and frail populations using new combinations at full or 
reduced doses. As an example, in the MAIA trial, continuous daratumumab-Rd significantly 
prolonged PFS compared to continuous Rd, but a higher incidence of infections and a lower 
lenalidomide cumulative dose due to dose reduction/discontinuation were noted in the 
daratumumab-Rd arm.
23
 Regarding maintenance, data about mAbs + IMiDs combination 
outside of the context of continuous therapy are not currently available in elderly patients. In 
the experimental arm of the ALCYONE trial, daratumumab monotherapy after daratumumab-
VMP quadruplet induction was well tolerated and improved duration and depth of response.
24
 
A longer follow-up of these two studies will inform us about the safety of mAbs maintenance 
and the feasibility of long-term treatment with mAbs + IMiDs in elderly patients. 
Our analysis has some limitations. The trial was designed to show superiority of a 3-drug 
induction regimen over a 2-drug induction regimen in the overall population, and thus the 
study power was not enough to detect a statistically significant difference in the frailty 
subgroups. However, the outcome differences between treatment arms in fit patients were 
high enough to reach significant levels. 
12 
 
Moreover, our analysis based on the frailty status was not pre-specified, but the geriatric 
assessment adopted to calculate the IMWG Frailty Score was obtained from the enrolled 
patients before the start of therapy. Although patients’ allocation to treatment arms was not 
stratified by IMWG Frailty Score, the stratification by age led to a uniform distribution of 
fit/intermediate-fit/frail patients across treatment arms.  
In conclusion, this trial showed that the triplet MPR prolonged progression-free-survival 
compared to gentler regimens in elderly fit but not in intermediate-fit and frail MM patients. 
In intermediate-fit and frail patients, in the absence of differences in terms of efficacy, safety 
must be prioritized. Maintenance with lenalidomide-based regimens led to good outcomes 
with a good safety profile.  
These data provide the basis for a personalized treatment according to patients’ frailty status. 
Different combinations of new-generation IMiDs, PIs and mAbs should be evaluated in fit, 
intermediate-fit and frail patients to confirm these observations. Novel compounds with a 
good safety profile in combination with a lenalidomide-based maintenance treatment should 
also be explored in elderly patients. 
 
Role of the funding source 
The EMN01 study (NCT01093196) was sponsored by Fondazione Neoplasie Sangue [FO.NE.SA.] ONLUS (Italy) 
and supported by funding from Celgene, which had no role in study design, data collection, data analysis, data 
interpretation, writing of the report or publication of this contribution. The corresponding author had full access 
to all the data in the EMN01 study and had final responsibility for the decision to prepare and submit this 
manuscript for publication, together with the other authors. 
 
Acknowledgements 
We thank all the patients who participated in the study, the nurses Silvia Boscolo and Concetta Calicchio and the 
data managers Antonella Fiorillo and Elena Tigano. 
 
Contributors 
Substantial contributions to the conception or design: SB, AP, MB, and AL. 
Acquisition, analysis, or interpretation of data: all authors. 
First draft: SB and MD 
Statistical analysis: SS. 
Critical revision for important intellectual content: all authors. 
Final approval of the version to be published: all authors. 
Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or 
integrity of any part of the work are appropriately investigated and resolved: all authors. 
Supervision: SB, MB, and AL. 
 
Conflicts of Interest 
SB has received honoraria from Bristol-Myers Squibb, Celgene, Amgen and Janssen; has served on the advisory 
boards for Amgen, Janssen, Celgene, and Karyopharm; and has undertaken consultancy for Takeda and Janssen.  
StB has received honoraria from Celgene, Jannsen, Bristol-Myers Squibb, and Amgen. 
SA has served on the advisory boards for Celgene and Amgen. 
AS has served on the advisory boards for Bristol-Myers-Squibb, Servier, Gilead, Pfizer, Eisai, Bayer, Merck Sharp 
& Dohme; has participated in the speaker’s bureaus for Takeda, Bristol-Myers-Squibb, Roche, AbbVie, Amgen, 
Celgene, Servier, Gilead, Astrazeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, and Merck Sharp & 
Dohme. 
13 
 
MTP has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Takeda, and served on the 
advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda. 
RM has received honoraria from Janssen, AbbVie, Gilead, Roche; has received a research grant from Janssen; has 
served on the advisory boards for Janssen, Shire, and Roche. 
AP is currently a Takeda employee; data reported here have been generated during his previous Investigator 
role, and are not reflecting any Takeda’s position. He has ownership interests (including stock options) in 
Takeda. All the following AP’s conflicts of interest refer to a period of more than two years ago: he had received 
honoraria from and undertook consultancy for Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, 
Janssen-Cilag, Takeda, Sanofi Aventis, and Merck; he had received research funding from Amgen, Novartis, 
Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis, Merck, and Binding Site; he 
had served on the Speakers’ Bureau for Bristol-Myers Squibb. 
RH has received honoraria from Amgen, Bristol-Myers Squibb, Takeda, Celgene, Janssen; has received research 
funding from Takeda, Novartis, Amgen, Janssen; had a consultant or advisory relationship with Amgen, Takeda, 
Bristol-Myers Squibb, Celgene, and Janssen. 
MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, AbbVie, and Bristol-Myers Squibb; 
has received research funding from Celgene, Janssen, Amgen, Bristol-Myers Squibb, Mundipharma, Novartis, and 
Sanofi. 
AL has received honoraria from Amgen, Bristol-Myers Squibb, Celgene and Janssen-Cilag; has served on the 
advisory boards for Bristol-Myers Squibb, Celgene, Janssen-Cilag, and Takeda. 
The remaining authors declare no competing financial interests. 
 
 
References 
1.  Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-60. 
2.  Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus 
thalidomide compared with melphalan and prednisone alone in elderly patients with multiple 
myeloma: randomised controlled trial. Lancet. 2006;367(9513):825-831. 
3.  San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial 
treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917. 
4.  Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in 
transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906-917. 
5.  Palumbo A, Hajek R, Delforge M, et al. Continuous Lenalidomide Treatment for Newly Diagnosed 
Multiple Myeloma. N Engl J Med. 2012;366(19):1759-1769. 
6.  Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients 
with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 
3 trial. Lancet Oncol. 2019;20(1):57-73. 
7.  Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous 
transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in 
patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 
2015;16(16):1617-1629. 
8.  Larocca A, Dold SM, Zweegman S, et al. Patient-centered practice in elderly myeloma patients: an 
overview and consensus from the European Myeloma Network (EMN). Leukemia 2018;32(8):1697-
1712. 
9.  Salvini M, D’Agostino M, Bonello F, Boccadoro M, Bringhen S. Determining treatment intensity in 
elderly patients with multiple myeloma. Expert Rev Anticancer Ther. 2018;18(9):917-930. 
10.  Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for 
the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016;127(9):1102-
1108. 
11.  Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in 
elderly myeloma patients: An International Myeloma Working Group report. Blood. 
2015;125(13):2068-2074. 
12.  Franssen LE, Nijhof IS, Bjorklund CC, et al. Lenalidomide combined with low-dose 
cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in 
immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. Oncotarget. 
2018;9(74):34009-34021. 
13.  Nakagawa M, Terashima T, D’yachkova Y, Bondy GP, Hogg JC, van Eeden SF. Glucocorticoid-
14 
 
induced granulocytosis: contribution of marrow release and demargination of intravascular 
granulocytes. Circulation. 1998;98(21):2307-2313. 
14.  Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone 
for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152. 
15.  Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with 
lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 
2012;120(9):1801-1809. 
16.  Facon T, Hulin C, Dimopoulos MA, et al. A Frailty Scale Predicts Outcomes of Patients with Newly 
Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous 
Lenalidomide Plus Low-Dose Dexamethasone on the First Trial. Blood. 2015;126(23):4239. 
17.  Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 
FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301-310. 
18.  Facon T, Kumar SK, Plesner T, et al. Phase 3 Randomized Study of Daratumumab Plus 
Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients 
with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). Blood. 
2018;132(Suppl 1):LBA-2. 
19.  Larocca A, Salvini M, De Paoli L, et al. Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R 
Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) 
Patients: RV-MM-PI-0752 Phase III Randomized Study. Blood. 2018;132(Suppl 1):305. 
20.  Durie BG, Hoering A, Sexton R, et al. Longer Term Follow Up of the Randomized Phase III Trial 
SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and 
Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for 
Immediate Autologous Stem. Blood. 2018;132(Suppl 1):1992. 
21.  Mateos M-V, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and 
Prednisone for Untreated Myeloma. N Engl J Med. 2018;378(6):518-528. 
22.  Ocio EM, Otero PR, Bringhen S, et al. Preliminary Results from a Phase I Study of Isatuximab (ISA) 
in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd) in Patients with Newly 
Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant. Blood. 2018;132(Suppl 1):595. 
23.  Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide and Dexamethasone for 
Untreated Myeloma. N Engl J Med. 2019;380(22):2104-2115. 
24.  Dimopoulos MA, Mateos M-V, Cavo M, et al. One-Year Update of a Phase 3 Randomized Study of 
Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, 
Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed 
Multiple Myeloma (NDMM): Alcyone. Blood. 2018;132(Suppl 1):156. 
  
15 
 
Tables 
 
Table 1. Demographics and baseline characteristics of the patients receiving maintenance 
treatment 
 
 
Patient characteristics Lenalidomide (R) 
(n=204) 
Lenalidomide- Prednisone (RP) 
(n=198) 
Age (years) 50-89 65-87 
Median 73 73 
>75 years (%) 61 (30%) 64 (32%) 
Sex (male) 86(42%) 105 (53%) 
Karnofsky score 60-100 60-100 
Median 90 90 
<80 (%) 37 (18%) 43 (22%) 
Fitness   
Fit 101 (50%) 91 (46%) 
Intermediate-fit 63 (31%) 58 (29%) 
Frail 40 (20%) 49 (25%) 
Clearance creatinine 
(ml/min) 
30-168.9 30-150 
Median (ml/min) 72 70 
International Staging 
System score 
  
I 65 (32%) 65 (33%) 
II 92 (45%) 88 (44%) 
III 47 (23%) 45 (23%) 
Cytogenetic abnormalities 
at FISH 
  
Data available 163 (80%) 162 (82%) 
Data missing 41 (20%) 36 (18%) 
High risk* 36 (18%) 37 (19%) 
* At least one among deletion 17p [del(17p)] or translocation (4;14) [t(4;14)] or translocation (14;16) [t(14;16)]. 
FISH, Fluorescence in situ hybridization. 
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Table 2. Grade ≥3 adverse events during maintenance treatment 
 
 
Grade ≥3 Adverse Events Lenalidomide (R) (n=204) 
Lenalidomide- Prednisone (RP) 
(n=198) 
Hematologic    
At least one event 46 (23%) 26 (13%) 
Anemia 4 (2%) 4 (2%) 
Neutropenia 43 (21%) 19 (10%) 
Thrombocytopenia 4 (2%) 5 (3%) 
Non-hematologic    
At least one event 22 (11%) 28 (14%) 
Cardiologic 2 (1%) 1 
 Acute Myocardial infarction 1 1  
 Other 1 0 
Vascular 5 (2%) 4 (2%) 
 Deep Vein Thrombosis 
 /Thromboembolism 
2 (1%) 3 (2%) 
Renal 1 2 (1%) 
Dermatologic 2 (1%) 3 (2%) 
Infection 2 (1%) 4 (2%) 
 Pneumonia 0 1 
 Bronchitis 1 1 
 Sepsis 0 1 
 Other/not specified 1 1 
Nervous 2 (1%) 7 (4%) 
Second primary malignancies 9 (4%) 6 (3%) 
 Hematologic  0 0 
 Solid 9 (4%) 6 (3%) 
Other 9 (4%) 5 (3%) 
Discontinuation due to 
adverse events 
36 (18%) 41 (21%) 
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Table 3. Grade ≥3 hematologic adverse events, non-hematologic adverse events, treatment 
discontinuation due to adverse events and toxic deaths during induction treatment according 
to patients’ frailty status 
 
 
Treatment arm 
(n) 
CPR 
(n=220) 
MPR 
(n=211) 
Rd 
(n=212) 
Frailty Score 
class (n) Fit (98) 
Intermediate-
fit 
(69) 
Frail  
(53) 
Fit 
(88) 
Intermediate-
fit 
(76) 
Frail 
(47) 
Fit 
(94) 
Intermediate
-fit 
(57) 
Frail 
(61) 
Hematologic 
AEs G ≥3, n (%) 31 (32) 23 (33) 17 (32) 62 (70) 46 (61) 35 (74) 26 (28) 13 (23) 22 (36) 
Non-hematologic 
AEs G ≥3, n (%) 22 (22) 22 (32) 22 (42) 22 (25) 22 (29) 22 (45) 24 (26) 15 (26) 24 (39) 
Discontinuation 
due to AEs, n 
(%) 
8 (8) 9 (13) 16 (30) 10 (11) 17 (22) 10 (21) 9 (10) 9 (16) 12 (20) 
Death due to 
AEs, n (%) 1 (1) 0 7 (13) 1 (1) 2 (3) 2(4) 1 (1) 1 (2) 4 (7) 
CPR: cyclophosphamide-prednisone-lenalidomide; MPR: melphalan-prednisone-lenalidomide; Rd: lenalidomide-
dexamethasone; AEs: adverse events; G: grade; n: number; %: percentage. 
 
 
 
 
Table 4. Grade ≥3 hematologic adverse events, non-hematologic adverse events, treatment 
discontinuation and toxic deaths during maintenance treatment according to patients’ frailty 
status 
 
 
Treatment arm (n) Lenalidomide (R) 
(n=204) 
Lenalidomide- Prednisone (RP) 
(n=198) 
Frailty Score class 
(n) Fit (101) 
Intermediate-
fit 
(63) 
Frail  
(40) 
Fit 
(91) 
Intermediate-
fit 
(58) 
Frail 
(49) 
Hematologic AEs G 
≥3, n (%) 24 (24) 13 (21) 9 (22) 10 (11) 6 (10) 10 (20) 
Non-hematologic 
AEs G ≥3, n (%) 12 (12) 5 (8) 5 (12) 12 (13) 9 (16) 7 (14) 
Discontinuation due 
to AEs, n (%) 16 (16) 9 (14) 11 (28) 14 (15) 16 (28) 11 (22) 
Death due to AEs, n 
(%) 2 (2) 1 (2) 2 (5) 2 (2) 2 (3) 4 (8) 
R: lenalidomide; RP: lenalidomide-prednisone; AEs: adverse events; G: grade; n: number; %: percentage. 
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Figure Titles and Legends 
 
 
 
Figure 1. Survival outcomes according to induction treatment arm  
Progression-free survival (PFS, panel A), Time to next treatment (TNT, panel B), Progression-free survival 2 
(PFS-2, panel C) and Overall survival (OS, panel D) are shown.  
All time to events were calculated from the time of random assignment to induction treatment arms.  
Abbreviations: MPR, melphalan-prednisone-lenalidomide; CPR, cyclophosphamide-prednisone-lenalidomide; Rd, 
lenalidomide-dexamethasone; PFS, progression-free survival; TNT, time to next treatment; OS, overall survival; HR, 
hazard ratio; CI, confidence interval; p, p value. 
 
 
Figure 2. Post-hoc analysis according to frailty status in patients treated with different induction 
treatments 
Panel A and B show PFS and OS in fit patients according to treatment arm; Panel C and D show PFS and OS 
in intermediate-fit patients according to treatment arm; Panel E and F show PFS and OS in frail patients 
according to treatment arm.  
All time to events were calculated from the time of random assignment to induction treatment arms. 
Abbreviations: MPR, melphalan-prednisone-lenalidomide; CPR, cyclophosphamide-prednisone-lenalidomide; Rd, 
lenalidomide-dexamethasone; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence 
interval; p, p value. 
 
 
Figure 3. Survival outcomes according to maintenance treatment arm 
Progression-free survival (PFS, panel A), Time to next treatment (TNT, panel B), Progression-free survival 2 
(PFS-2, panel C) and Overall survival (OS, panel D) are shown.  
All time to events were calculated from the time of random assignment to maintenance treatment arms. 
Abbreviations: R, lenalidomide; RP, lenalidomide-prednisone; PFS, progression-free survival; TNT, time to next 
treatment; OS, overall survival; HR, hazard ratio; CI, confidence interval; p, p value. 
 
 
Figure 4. Post-hoc analysis according to frailty status in patients treated with different maintenance 
treatments  
Panel A and B shows PFS and OS in fit patients according to treatment arm; Panel C and D shows PFS and 
OS in intermediate-fit patients according to treatment arm; Panel E and F shows PFS and OS in frail patients 
according to treatment arm.  
All time to events were calculated from the time of random assignment to maintenance treatment arms. 
Abbreviations: R, lenalidomide; RP, lenalidomide-prednisone; PFS_m, progression-free survival from the random 
assignment to maintenance arm; OS, overall survival from the random assignment to maintenance arm; HR, hazard 
ratio; CI, confidence interval; p, p value. 
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Additional procedures. Antithrombotic prophylaxis 
Antithrombotic prophylaxis was mandatory: aspirin or low-molecular weight heparin or warfarin 
were permitted at physician’s discretion. 
 
Endpoints and assessments 
The primary endpoint was progression-free survival (PFS); secondary endpoints included response 
rate, time to the first evidence of response, overall survival (OS), and incidence of grade ≥3 adverse 
events (AEs).  
Response and progression were assessed after each cycle during induction and then every 6 to 8 weeks 
until PD. After PD was confirmed, patients were followed every 90 days to document subsequent 
treatment and survival status. All time to events were calculated from the time of random assignment 
to induction arm for the analysis on induction treatment. All time to events in the analysis of 
maintenance treatment were calculated from the random assignment to maintenance arm. PFS was 
calculated from the time of random assignments until the date of progression, relapse, death as a result 
of any cause, or the date the patient was last known to be in remission. Time to next treatment (TNT, 
post-hoc analysis) was calculated from the time of random assignments until the date the subsequent 
myeloma therapy was administered at progression or relapse, the date of death from any cause, or the 
date the patient was last known to be in remission. Progression-free survival 2 (PFS-2, post-hoc 
analysis) was calculated from the time of random assignments until the date of second progression or 
death for any cause or the date the patient was last known to be alive. PFS-2 was evaluated in order to 
detect possible negative effects of a maintenance-containing first-line treatment on the subsequent line 
of therapy.1 OS was calculated from the time of random assignments until the date of death for any cause 
or the date the patient was last known to be alive. The response to treatment was defined by using 
International Uniform Response Criteria.2 All AEs were assessed at each visit and graded according to 
the National Cancer Institute’s Common Terminology Criteria for Adverse Events (v3.0).3 
 
Statistical analysis: supplementary information 
For the comparisons between (i) doublet vs triplet regimens, (ii) melphalan-prednisone-lenalidomide 
(MPR) vs lenalidomide-dexamethasone (Rd) and (iii) MPR vs cyclophosphamide-prednisone-
lenalidomide (CPR), time to event data were analyzed with Cox proportional hazards models adjusted 
for International Staging System (ISS) stage, cytogenetic risk defined by fluorescence in situ 
hybridization (FISH), and age. Cox models for maintenance comparison between lenalidomide-
prednisone (RP) and lenalidomide (R) were adjusted for induction treatment, ISS stage, cytogenetic risk 
defined by FISH, and age. A post-hoc analysis according to patient frailty was performed using 
interaction terms between treatment arm and IMWG frailty score (fit, intermediate-fit and frail 
patients). 
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Supplementary table S1. Geriatric score to define patients’ frailty status 
 
Parameter Score 
Age  
≤75 years 0 
76-80 years 1 
>80 years 2 
ADL   
>4 0 
≤4 1 
IADL   
>5 0 
≤5 1 
CCI   
≤1 0 
≥2 1 
Patient status Additive total score 
Fit 0 
Intermediate-fit 1 
Frail ≥2 
 
ADL, Activities of Daily Living; IADL, Instrumental Activities of Daily Living; CCI, Charlson Comorbidity Index. 
 
 
 
 
Supplementary table S2. Grade ≥3 hematologic adverse events, non-hematologic adverse events, treatment 
discontinuation due to adverse events and toxic deaths in the induction and maintenance population according 
to patients’ frailty status 
 
Trial population 
(n) 
Induction 
(n=643) 
Maintenance 
(n=402) 
Frailty Score 
class (n) 
Fit 
(280) 
Int 
(202) 
Frail 
(161) Chi-squared test 
Fit 
(192) 
Int 
(121) 
Frail 
(89) Chi-squared test 
Haematologic 
AEs G ≥3, n (%) 
119 
(43) 82 (41) 74 (46) 
Int vs Fit: NS 
Frail vs Fit: NS 34 (18) 19 (16) 19 (21) 
Int vs Fit: NS 
Frail vs Fit: NS 
Non-haematologic 
AEs G ≥3, n (%)  68 (24) 59 (29) 68 (42) 
Int vs Fit: NS 
Frail vs Fit: p < 0.01 24 (13) 14 (12) 12 (13) 
Int vs Fit: NS 
Frail vs Fit: NS 
Discontinuation 
due to AEs, n (%) 27 (10) 35 (17) 38 (24) 
Int vs Fit: p = 0.02 
Frail vs Fit: p < 0.01 30 (16) 25 (21) 22 (25) 
Int vs Fit: NS 
Frail vs Fit: p=0.10 
Death due to AEs, 
n (%) 3 (1) 3 (1) 13 (8) 
Int vs Fit: NS 
Frail vs Fit: p<0.01 4 (2) 3 (2) 6 (7) 
Int vs Fit: NS 
Frail vs Fit: p = 0.10 
 
AEs, adverse events; G, grade; n, number; %, percentage; Int, intermediate-fit; NS, p>0.10. 
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Supplementary figure S1. Patient disposition 
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Supplementary figure S2. Progression-free survival according to alkylator-containing induction 
treatment (MPR + CPR, "Alk”) vs alkylator-free induction treatment (Rd, “Non-Alk") 
 
 
 
 
MPR, melphalan-prednisone-lenalidomide; CPR, cyclophosphamide-prednisone-lenalidomide; Rd, lenalidomide-
dexamethasone; Alk, alkylator-containing induction treatment; Non-Alk, alkylator-free induction treatment; HR, hazard 
ratio; CI, confidence interval; p, p value.  
Non-Alk vs. Alk: HR 1.05, 95% CI 0.87-1.25, p=0.62 
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Supplementary figure S3. Induction treatment - Subgroup analysis according to cytogenetic risk 
 
MPR vs. CPR (PFS, PFS2 and OS); MPR vs. Rd (PFS, PFS2 and OS). 
 
 
3A. MPR vs. CPR - PFS 
 
 
 
 
 
3B. MPR vs. CPR - PFS2 
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3C. MPR vs. CPR - OS 
 
 
 
 
 
3D. MPR vs. Rd - PFS 
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3E. MPR vs. Rd - PFS2 
 
 
 
 
 
3F. MPR vs. Rd - OS 
 
 
 
 
Abbreviations. MPR, melphalan-prednisone-lenalidomide; CPR, cyclophosphamide-prednisone-lenalidomide; Rd, 
lenalidomide-dexamethasone; PFS, progression-free survival; PFS2, progression-free survival 2; OS, overall survival; FISH, 
fluorescence in situ hybridization; HR, hazard ratio; CI, confidence interval; Interaction-p, interaction p-value. 
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Supplementary figure S4. Maintenance treatment - Subgroup analysis according to cytogenetic risk 
 
RP vs. R (PFS, PFS2 and OS) 
 
 
4A. RP vs. R - PFS 
 
 
 
 
 
4B. RP vs. R - PFS2 
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4C. RP vs. R - OS 
 
 
 
 
Abbreviations. RP, lenalidomide-prednisone; P, prednisone; PFS, progression-free survival; PFS2, progression-free survival 
2; OS, overall survival; FISH, fluorescence in situ hybridization; HR, hazard ratio; CI, confidence interval; Interaction-p, 
interaction p-value.  
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